CVS
Strong BuySecond WindAI neutralCVS Health Corporation · Healthcare · United States · $119.5B cap · $814.8M/day traded
$91.41 +3.3% · close 3 Nov · scored 4 Nov
Second Wind: Cheap with strong momentum, but the business does not earn the optimism.
Report expected 4 Nov: the next-year EPS estimate has risen 1.4% over the last 13 weeks.
As of 4 Nov 2026, MoatMap's StockRank for CVS Health Corporation (CVS) is 92/100, ranked against 24,000+ stocks in 35 markets (Quality 50, Value 69, Momentum 76, each scored against its sector).
Does StockRank work? Each month we publish how each tenth of the ranking did, whichever way it went. See the record →
CVS Health combines the Aetna insurer, the Caremark pharmacy benefit manager and the largest US retail pharmacy chain. Aetna margins have been recovering after repricing, and the valuation remains modest relative to earnings power, which explains the strong momentum. However, this is a restructuring and margin-recovery story, with PBM reform, Medicare Advantage rate risk and retail pharmacy decline all live issues, so it lacks the durable compounding profile needed for a strong case.
ABOUT CVS HEALTH CORPORATION
Read
CVS Health Corporation is an integrated healthcare company operating retail pharmacies (CVS Pharmacy), pharmacy benefit management services (CVS Caremark), and health insurance plans (Aetna). Its competitive moat is built on unmatched scale and vertical integration across pharmacy, PBM, and insurance segments, creating a comprehensive healthcare ecosystem. CVS Health is one of the largest integrated healthcare providers in the U.S., offering a broad range of health services.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 322.5B | 357.8B | 372.8B | 402.1B | 7.6% | 412.6B | 418.0B | 430.0B | 3.4% |
| EPS | 3.29 | 6.49 | 3.67 | 1.40 | -24.8% | 3.80 | 1.67 | 1.77 | 12.4% |
| Shares | 1.3B | 1.3B | 1.3B | 1.3B | -2.2% | 1.3B | — | — | — |
| Debt | 70.7B | 79.4B | 82.9B | 80.0B | 4.2% | 76.3B | — | — | — |
| Equity | 71.5B | 76.5B | 75.6B | 75.2B | 1.7% | — | — | — | — |
| Op CF | 16.2B | 13.4B | 9.1B | 10.6B | -13.0% | 14.8B | — | — | — |
| Inv CF | -5.0B | -20.9B | -7.6B | -5.9B | — | — | — | — | — |
| Fin CF | -10.5B | 2.7B | -1.1B | -4.9B | — | — | — | — | — |
No clear trend: not near its 52-week low, and not in a steady uptrend.
Calmer than 70% of stocks we rank over the past year (volatility 31% a year).
How this is worked out
StockRank weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CVS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CVS | CVS Health Corporation(you) | $119.5B | 92 | Strong Buy |
| ELV | Elevance Health, Inc. | $95.4B | 93 | Strong Buy |
| CI | The Cigna Group | $81.1B | 93 | Strong Buy |
| HUM | Humana Inc. | $50.7B | 88 | Strong Buy |
| CNC | Centene Corporation | $34.7B | 94 | Strong Buy |
| UNH | UnitedHealth Group Incorporated | $375.3B | 87 | Strong Buy |
| OSCR | Oscar Health, Inc. | $9.6B | 99 | Strong Buy |
| SAUD3.SA | Bradsaúde S.A. | $9.7B | 99 | Strong Buy |
| PGNY | Progyny, Inc. | $2.2B | 94 | Strong Buy |
| MOH | Molina Healthcare, Inc. | $10.9B | 49 | Hold |
Peer medians: ROE 2.7% · P/E 23.0x · Gross margin 53.9%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.